IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) - Net Assets
Based on the latest financial reports, IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) has net assets worth €4.34 Billion EUR (≈ $5.07 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€6.94 Billion ≈ $8.11 Billion USD) and total liabilities (€2.60 Billion ≈ $3.04 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) cash conversion ratio to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.34 Billion |
| % of Total Assets | 62.51% |
| Annual Growth Rate | 12.19% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 6.77 |
IPSEN SA SP.ADR 1/4/ EO 1 - Net Assets Trend (2021–2025)
This chart illustrates how IPSEN SA SP.ADR 1/4/ EO 1's net assets have evolved over time, based on quarterly financial data. Also explore IPSEN SA SP.ADR 1/4/ EO 1 assets under control for the complete picture of this company's asset base.
Annual Net Assets for IPSEN SA SP.ADR 1/4/ EO 1 (2021–2025)
The table below shows the annual net assets of IPSEN SA SP.ADR 1/4/ EO 1 from 2021 to 2025. For live valuation and market cap data, see I7G0 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €4.34 Billion ≈ $5.07 Billion |
+3.71% |
| 2024-12-31 | €4.18 Billion ≈ $4.89 Billion |
+9.36% |
| 2023-12-31 | €3.82 Billion ≈ $4.47 Billion |
+14.37% |
| 2022-12-31 | €3.34 Billion ≈ $3.91 Billion |
+22.12% |
| 2021-12-31 | €2.74 Billion ≈ $3.20 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to IPSEN SA SP.ADR 1/4/ EO 1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 31.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €443.50 Million | 10.23% |
| Other Components | €3.89 Billion | 89.77% |
| Total Equity | €4.34 Billion | 100.00% |
IPSEN SA SP.ADR 1/4/ EO 1 Competitors by Market Cap
The table below lists competitors of IPSEN SA SP.ADR 1/4/ EO 1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Unum Group
NYSE:UNM
|
$12.92 Billion |
|
Dycom Industries Inc
NYSE:DY
|
$12.94 Billion |
|
Fidelity National Financial Inc
NYSE:FNF
|
$12.94 Billion |
|
GD Power Development Co Ltd
SHG:600795
|
$12.95 Billion |
|
RPM International Inc
NYSE:RPM
|
$12.91 Billion |
|
Mapfre
MC:MAP
|
$12.91 Billion |
|
Anhui Jianghuai Automobile Group Corp Ltd
SHG:600418
|
$12.90 Billion |
|
URW (STAPL.SHS CDI)EO-05
F:UBLB
|
$12.89 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IPSEN SA SP.ADR 1/4/ EO 1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,181,600,000 to 4,335,900,000, a change of 154,300,000 (3.7%).
- Net income of 443,500,000 contributed positively to equity growth.
- Dividend payments of 116,200,000 reduced retained earnings.
- Share repurchases of 67,700,000 reduced equity.
- Other factors decreased equity by 105,300,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €443.50 Million | +10.23% |
| Dividends Paid | €116.20 Million | -2.68% |
| Share Repurchases | €67.70 Million | -1.56% |
| Other Changes | €-105.30 Million | -2.43% |
| Total Change | €- | 3.69% |
Book Value vs Market Value Analysis
This analysis compares IPSEN SA SP.ADR 1/4/ EO 1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.78x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.23x to 0.78x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €33.16 | €40.80 | x |
| 2022-12-31 | €40.47 | €40.80 | x |
| 2023-12-31 | €46.25 | €40.80 | x |
| 2024-12-31 | €50.56 | €40.80 | x |
| 2025-12-31 | €52.63 | €40.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IPSEN SA SP.ADR 1/4/ EO 1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.23%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.29%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.60x
- Recent ROE (10.23%) is below the historical average (15.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 23.64% | 23.52% | 0.55x | 1.82x | €373.08 Million |
| 2022 | 19.40% | 20.55% | 0.56x | 1.68x | €314.20 Million |
| 2023 | 16.85% | 19.49% | 0.52x | 1.65x | €261.89 Million |
| 2024 | 8.27% | 9.68% | 0.56x | 1.54x | €-72.26 Million |
| 2025 | 10.23% | 11.29% | 0.57x | 1.60x | €9.91 Million |
Industry Comparison
This section compares IPSEN SA SP.ADR 1/4/ EO 1's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $6,058,012,174
- Average return on equity (ROE) among peers: -98.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) | €4.34 Billion | 23.64% | 0.60x | $12.92 Billion |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $54.11 Billion | 6.89% | 0.98x | $1.19 Billion |
| PEPTONIC MEDICAL (28L) | $75.32 Million | -56.54% | 0.42x | $4.14 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $5.95 Billion | 11.12% | 0.39x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $201.51 Million | -13.72% | 0.07x | $157.72 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-8.51 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $29.16 Million | -49.27% | 0.13x | $13.93 Million |
| EQL PHARMA AB (7JK) | $221.03 Million | 19.51% | 2.66x | $80.44 Million |
About IPSEN SA SP.ADR 1/4/ EO 1
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more